These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28651152)

  • 1. Methylphenidate disintegration from oral formulations for intravenous use by experienced substance users.
    Bjarnadottir GD; Johannsson M; Magnusson A; Rafnar BO; Sigurdsson E; Steingrimsson S; Asgrimsson V; Snorradottir I; Bragadottir H; Haraldsson HM
    Drug Alcohol Depend; 2017 Sep; 178():165-169. PubMed ID: 28651152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous Use of Prescription Psychostimulants; A Comparison of the Pattern and Subjective Experience between Different Methylphenidate Preparations, Amphetamine and Cocaine.
    Bjarnadottir GD; Magnusson A; Rafnar BO; Sigurdsson E; Steingrimsson S; Johannsson M; Bragadottir H; Haraldsson HM
    Eur Addict Res; 2016; 22(5):259-67. PubMed ID: 27287610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder.
    Golubchik P; Kodesh A; Weizman A
    Clin Neuropharmacol; 2017; 40(1):11-15. PubMed ID: 27879551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Methylphenidate Levels in Youths With Attention Deficit Hyperactivity Disorder Treated With OROS Formulation.
    Yorbik O; Mutlu C; Ozilhan S; Eryilmaz G; Isiten N; Alparslan S; Saglam E
    Ther Drug Monit; 2015 Jun; 37(3):347-52. PubMed ID: 25384118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria.
    Shram MJ; Quinn AM; Chen N; Faulknor J; Luong D; Sellers EM; Endrenyi L
    Clin Ther; 2012 May; 34(5):1170-81. PubMed ID: 22512898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.
    Gau SS; Shen HY; Soong WT; Gau CS
    J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):441-55. PubMed ID: 16958569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of pharmacokinetic profile and timing of coadministration of short- and long-acting formulations of methylphenidate on patterns of subjective responses and abuse potential.
    Spencer TJ; Biederman J; Martin JM; Moorehead TM; Mirto T; Clarke A; Batchelder H; Faraone SV
    Postgrad Med; 2012 Jan; 124(1):166-73. PubMed ID: 22314126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
    Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
    Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCB1 c.2677G>T variation is associated with adverse reactions of OROS-methylphenidate in children and adolescents with ADHD.
    Kim SW; Lee JH; Lee SH; Hong HJ; Lee MG; Yook KH
    J Clin Psychopharmacol; 2013 Aug; 33(4):491-8. PubMed ID: 23771192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder.
    Biederman J; Mick EO; Surman C; Doyle R; Hammerness P; Michel E; Martin J; Spencer TJ
    BMC Psychiatry; 2007 Sep; 7():49. PubMed ID: 17868455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
    Wigal SB; Gupta S; Heverin E; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
    Steele M; Weiss M; Swanson J; Wang J; Prinzo RS; Binder CE
    Can J Clin Pharmacol; 2006; 13(1):e50-62. PubMed ID: 16456216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
    Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
    Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder.
    Winhusen TM; Lewis DF; Riggs PD; Davies RD; Adler LA; Sonne S; Somoza EC
    J Child Adolesc Psychopharmacol; 2011 Oct; 21(5):455-63. PubMed ID: 22040190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
    Marcus SC; Wan GJ; Kemner JE; Olfson M
    Arch Pediatr Adolesc Med; 2005 Jun; 159(6):572-8. PubMed ID: 15939858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD.
    Kim Y; Shin MS; Kim JW; Yoo HJ; Cho SC; Kim BN
    Hum Psychopharmacol; 2009 Mar; 24(2):95-102. PubMed ID: 19226534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
    Takahashi N; Koh T; Tominaga Y; Saito Y; Kashimoto Y; Matsumura T
    World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.